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Abstract 48 
Background: 49 
Few data describe the natural history of Charcot Neuroarthropathy treated with a 50 
total contact plaster cast (TCC).  51 
Methods: 52 
A 5 year retrospective analysis of 50 patients presenting with an acute CN, 53 
Assessing time to clinical resolution into appropriate footwear and assessing if 54 
initial immobilisation device influenced resolution time.  55 
Results: 56 
During the study period 42 patients (84%) of patients went into remission, 2 died 57 
during their treatment, 4 had major amputations, in 2 patients treatment was 58 
ongoing. 36 patients were treated with combination offloading devices, 6 were 59 
treated with one modality only. Median time to resolution for patients initially 60 
treated with a TCC was not significantly shorter than for those treated with a 61 
removable below knee boot.  34.9% required re-casting due to clinical 62 
deterioration in the removable device.  63 
Conclusions: 64 
More precise measures of resolution of CN are needed to assess the impact of 65 
initial treatment modality on time to resolution.  66 
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Introduction 75 
Diabetes mellitus (DM) is a common condition affecting 382 million people 76 
globally, a number predicted to rise to 592 million by 2035 [1]. Diabetic foot 77 
disease is a common problem globally, and has major consequences for patients 78 
and society in general [2]. Between 2010 and 2011 the estimated cost of 79 
diabetes related ulceration and amputation to England was £639-661 million [3]. 80 
This data also showed that regular contact with a specialist diabetic foot 81 
multidisciplinary team decreased the costs to the NHS [3].  82 
 83 
Charcot neuroarthropathy (CN) is an uncommon complication of diabetes. 84 
Population based studies have estimated a prevalence of CN of 0.1-0.5% in 85 
people with diabetes, rising to 13% in high risk patients [4]. Patients may present 86 
to any one of several different specialities such as orthopaedics, rheumatology or 87 
even accident and emergency departments. The diagnosis is frequently missed, 88 
and there is often a delay in starting treatment [5]. Once diagnosed, the 89 
treatment is immobilisation using a total contact plaster cast (TCC) or, if this is 90 
not available, a removable below knee walking boot [6]. It has been estimated 91 
that the average cost of managing a CN in community and outpatient setting is 92 
£2,710 per foot. The total cost for treating CN in the UK is over £6.5 million per 93 
annum [3].  94 
 95 
Whilst uncommon, CN can be a potentially devastating end-stage complication of 96 
diabetes mellitus. If there is a delay in treatment, CN is often associated with 97 
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progressive foot deformity and resultant ulceration and infection. For patients 98 
with an uncomplicated CN, the risk of amputation is <2% [7]. However, the 99 
presence of an ulcer increases the risk of amputation between 12-13 times [7].  100 
 101 
The pathogenesis of CN is presently poorly understood [6]. However, the 102 
longstanding theory regarding the pathophysiology of the disease - the 103 
neurotrophic theory originally described by Charcot, still has a role [8]. In 104 
addition, more recent work suggests that the inflammatory cascade plays an 105 
important role in developing the condition and may be a therapeutic target in the 106 
future [9]. 107 
 108 
A recent, large systematic review suggested that the current gold standard 109 
management of acute CN consists of immediate referral to a multidisciplinary 110 
foot-care team followed by immobilisation of the foot in a TCC [10]. These 111 
recommendations are consistent with the guidelines from the UK National 112 
Institute for Clinical and Health Care Excellence [11]. However, we acknowledge 113 
that there are variations in what people accept as the gold standard – with some 114 
centres using alternative methods of immobilisation such as the instant total 115 
contact cast or removable devices. A large prospective randomised trial is 116 
needed to address this. 117 
 118 
There are few data describing the natural history of CN, particularly when treated 119 
with the TCC. A recent multicentre observational study of patients with acute CN 120 
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found that median time to resolution was 9 months in patients treated initially with 121 
a non-removable offloading device, compared to 12 months in those treated 122 
initially with a removable offloading device [12]. The same authors also reported 123 
a major amputation rate of 3.1% (n=9).  124 
 125 
To further our understanding of the natural history of acute CN treated with TCC, 126 
we undertook a retrospective single centre study. Our aim was to look at time 127 
taken to achieve clinical resolution and to see if the initial device used to 128 
immobilise the foot influenced time to resolution. A secondary outcome was to 129 
see how many people relapsed when they came out of the TCC. A further 130 
secondary outcome was to see if the location of the Charcot influenced time to 131 
clinical resolution. 132 
 133 
  134 
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Methods 135 
We performed a retrospective analysis of patients presenting to a single centre 136 
tertiary foot clinic with a diagnosis of acute CN between October 2007 and 137 
October 2012. Patients were searched our electronic database using the 138 
keyword “Charcot”.  139 
 140 
Patients were included in the study if they had either type 1 or type 2 DM. The 141 
acute CN must have developed within the study period, and the patients must 142 
have been managed as an acute CN. Patients were excluded if an acute CN was 143 
deemed unlikely from the history and clinical examination, or if imaging studies 144 
were negative or another diagnosis was found to be causative or more likely. A 145 
strong clinical suspicion of acute CN with negative imaging studies would not 146 
exclude a patient from the study. Patients were also excluded if they had a 147 
chronic CN. 148 
 149 
Data collection was achieved by the examination of electronic hospital records 150 
and hand-written clinic notes. Baseline demographics for study subjects were 151 
recorded, as were details of the acute CN. We looked at the site of CN, method 152 
of treatment, time in treatment method, and time to resolution. Resolution was 153 
determined by the point of transition from treatment to either own or hospital 154 
supplied footwear. Data was also collected on complications such as amputation 155 
and mortality. Patients were followed-up until the end of the study period.  156 
 157 
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For baseline demographics such as HbA1c and retinopathy, the most recent 158 
value recorded within a one year timeframe either side of the diagnosis was 159 
used. This timeframe was set as often tests were last or next performed at the 160 
patients’ diabetes annual review. 161 
 162 
Site of CN was categorised into one of the following: forefoot; mid-foot; hind-foot 163 
and ankle; or mixed. A pre-defined classification criteria was not used as not all 164 
patients were diagnosed radiologically, leaving uncertainty around the exact 165 
location of the CN when it involved the hindfoot or ankle. 166 
 167 
Data were analysed using SAS statistical software, version 9.3 (Marlow, 168 
Buckinghamshire, UK). 169 
 170 
  171 
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Results 172 
50 patients were included. All patients had foot pulses palpable, and were 173 
insensate to 10g Semmes-Weinstein monofilament testing at the time of 174 
diagnosis of CN. However, 2 people died during the course of the study. Figure 1 175 
shows the numbers at each stage of the patient inclusion / exclusion criteria. All 176 
were diagnosed and managed at the same centre within the time period of the 177 
study. The specialist foot clinic was run by 2 of the authors (CG and KD) as part 178 
of the multidisciplinary foot clinic, which included 2 orthopaedic surgeons 179 
specialising in foot and ankle surgery.  180 
 181 
The mean age (±SD) at CN diagnosis was 62.5±11.7 years. 34 (68%) were male. 182 
11 (22%) had T1DM. The median duration of diabetes (IQR) was 32.0 years 183 
(19.8, 38.0) for those with T1DM, and 15.0 years (4.5, 20.0) for those with T2DM. 184 
Mean HbA1C (+SD) was 65±20mmol/mol (8.1%), (T1DM 70±19mmol/mol 185 
[8.6±3.9%]); T2DM 64±20mmol/mol [8.0±4.0%]).  186 
 187 
At diagnosis of acute CN 12 patients had chronic kidney disease (CKD) stage 0 188 
or 1, 21 patients (42%) had CKD stage 2 and 17 patients (34%) had CKD stage 189 
3-4. 9 patients had no evidence of retinopathy, 27 had a grading of R1 190 
(background), with 10 of these having R1, M1 (background retinopathy and 191 
macular involvement), 3 had R2 (pre-proliferative disease) – one of these had 192 
macular disease (R2 M1), 8 had R3 (proliferative retinopathy), 3 with macular 193 
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disease (R3 M1). 1 patient was recorded as having retinopathy with no grade 194 
given. Retinopathy data was unavailable for 2 patients. 195 
 196 
Of the 50 patients, only 15 were able to recall an episode of trauma to the 197 
affected foot within the preceding 12 months. During the study period, 4 patients 198 
had major amputations and 3 had minor amputations or debridement to the 199 
affected foot.  200 
 201 
40 patients (80%) had a difference in foot temperature of >2oC at presentation, 202 
with the affected foot being warmer. There was no data available for 4 (8%) 203 
patients. 6 patients (12%) had foot temperature difference of <2oC at 204 
presentation, however all of these were diagnosed and managed as acute CN on 205 
clinical grounds, with 4 of the 6 having an acute CN confirmed radiologically. In 206 
total, 30 patients (60%) had a diagnosis of acute CN confirmed radiologically, by 207 
X-ray, MRI or both. The others were treated on clinical grounds because they 208 
had presented with a hot, swollen, and deformed insensate foot but in whom 209 
repeated imaging showed no abnormality. All patients were followed up 210 
radiologically. 211 
 212 
Charcot site 213 
During the study, 42 patients went into remission, with foot temperatures <2oC for 214 
greater than 6 weeks (3 consecutive visits to the foot clinic) and stable 215 
radiographic imaging.  Of these 11.9% were in the forefoot, 64.3% in the mid-216 
A 
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foot, 19.1% in the hind-foot or ankle, with 4.8% in multiple sites.  Median times to 217 
resolution for CN depending on location were not significant (p=0.3814), and are 218 
shown in Table 1.  219 
 220 
Offloading device (Figures 2a and 2b) 221 
36 of the 42 patients who went into remission (85.7%) were treated with both 222 
TCC and removable offloading device. The removable offloading device was 223 
used to wean the patients out of the TCC and into footwear. 25 (59.5%) were 224 
initially treated with a TCC, whilst the remaining 17 (40.5%) started in a 225 
removable offloading device. 6 patients were treated with one modality only – 1 226 
patient was treated with TCC only, and the other 5 were treated with a removable 227 
offloading device only. For these 42 patients, median time to resolution was 51.5 228 
weeks (IQR 37-68). Of this, a median of 26 weeks (IQR 12-39) was spent in 229 
TCC, with 18 weeks (IQR 13-31) being spent in a removable offloading device.  230 
 231 
Median time to resolution for the 26 patients initially treated with a TCC was 48 232 
weeks (95% CI: 42.4, 64.4) compared to the median time of 53 weeks (95% CI: 233 
42.5, 64.4) for the 22 patients initially treated with removable offloading device (p 234 
= 0.7681, Appendix 1).   235 
 236 
43 patients out of the initial 50 patients in the study used a TCC at some stage 237 
during their treatment. Having achieved clinical remission using our standard 238 
definition, they transferred from a TCC into a removable device. However, 15 of 239 
A 
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these 43 (34.9%) relapsed and required re-casting due to clinical deterioration of 240 
the acute CN. The median time to resolution for these 15 patients was 68 weeks 241 
(95% CI: 53, 89) compared to the 32 patients who had no re-casting, who had a 242 
median time to resolution of 42.5 weeks (95% CI: 35, 48) (P<0.0001 log rank 243 
test). More work needs to be done to try and identify those who are at greatest 244 
risk of clinical deterioration or when the correct time to take the cast off. We used 245 
the standard clinical indicators of 3 consecutive clinical appointments at least 2 246 
weeks apart with a temperature difference of less than 2 degrees Celsius with 247 
stable radiological appearances to diagnose resolution of the CN [6].  248 
 249 
13 out of the initial 50 patients had an ulcer on the same foot as the acute CN at 250 
the start of treatment. Of these, 1 patient underwent below knee amputation 251 
whilst 12 went successfully into remission without further complication. In 3 252 
patients the CN was diagnosed when they presented with avulsion fractures to 253 
the foot.  254 
 255 
Whilst patients were in a cast, very few developed any complications as a result. 256 
All of these were minor - the most common being a rub. However, no patients 257 
changed their treatment as a consequence of these. In addition, outr clinic 258 
protocols mean that patients have their cast changed weekly or every other 259 
week, but in addition, they have ‘open access to the specialist foot clinic if they 260 
feel they have a problem with the cast. 261 
 262 
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Time to healing was not associated with the presence of chronic kidney disease, 263 
retinopathy, HbA1c or duration of diabetes (see Appendix 1).  264 
 265 
  266 
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Discussion 267 
 268 
This study has shown that 50 patients presented to our tertiary specialist foot 269 
clinic with a new diagnosis of Charcot neuroarthropathy during a 5 year period. 270 
When treated, the median time to resolution and transfer to appropriate footwear 271 
was 1 year (52.25 weeks, IQR 25, 81). Our study also showed a 34.9% 272 
deterioration rate after coming out of TCC, and found that re-plastering was 273 
found to be associated with a significantly increased time to resolution (p<0.0001, 274 
log rank test). This implies that despite clinical resolution of the acute phase of 275 
the Charcot process (a temperature difference of <2oC for 3 consecutive visits, 276 
each at least 2 weeks apart)[6] and a ‘step down’ into the removable below knee 277 
walking boot, those patients were taken out of the TCC too early. Another 278 
possible explanation for this is that the patients were more mobile than they had 279 
been advised to be, thus causing a reactivation of the Charcot process. However, 280 
our data is consistent with previous work that showed relapse rates vary, 281 
between 12% and 33% [13,14,15,16]. 282 
 283 
Our data further show that the longer the TCC remained on, the greater the time 284 
to resolution, but also a lower chance of subsequent deterioration. This is in 285 
contrast to the work by Christensen et al who showed that the use of a 286 
removable offloading device as the sole treatment method of acute CN led to 287 
average treatment duration of approximately 5 months [16]. This is significantly 288 
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less than the present study, or other authors who used TCC as a part of their 289 
management strategy [12,15].  290 
 291 
The current data take into account that our service covers a large, predominantly 292 
rural, geographical area and when patients are first diagnosed they have often 293 
driven to the clinic. Whilst we would prefer to offer them the gold standard 294 
treatment of the TCC at the time of diagnosis, we are aware of the significant 295 
negative impact this decision would have on their lives and so many opt to use 296 
the below knee removable walking boot for a few days until they arrange 297 
transport back to our clinic to go into a TCC.  We analysed whether this initial 298 
treatment modality had an impact on overall time to resolution.  It is likely that the 299 
non-statistically significant shorter time to resolution in those patients initially 300 
treated with a TCC is a reflection of the relatively small sample size. 301 
 302 
Whilst there is general consensus that immobilisation of the foot is necessary to 303 
prevent progression in the acute Charcot foot, there is generally poor quality 304 
evidence to differentiate between a TCC and a removable below knee walking 305 
boot [10]. The results of the current study are in contrast to those reported by the 306 
CDUK group who found that median time to resolution varies greatly between 307 
those initially treated in a non-removable device, e.g. a TCC compared to 308 
removable offloading device (9 months and 12 months respectively) [12]. That 309 
study, however, used data from many centres across the UK and there was no 310 
standardisation on set point or definition of ‘resolution’. This could have impacted 311 
16 
 
the duration of treatment. The authors also acknowledged that their work “may 312 
have been influenced by selection bias” despite their efforts to include all patients 313 
diagnosed with acute CN from each centre [12]. This made it difficult to draw 314 
conclusions on true treatment times because it was unknown which patients 315 
were and were not included. However, worldwide there is a significant variation in 316 
the median period of immobilisation; in the UK observational work has reported 317 
durations of 9-12 months [12], whilst data from the USA and other European 318 
centres reported periods of immobilisation for only 4-6 months [17,18,19]. We 319 
acknowledge that some of this variation may be due to differences in the 320 
offloading devices and techniques. For example, some areas may use double-321 
shelled orthosis adapted to the patient but removable and patellar tendon-322 
adapted, or in the US where the use of ‘knee scooters’ may be more prevalent. 323 
To address some of this variation in care, a national casting course has been 324 
developed in the UK [20].  Our results also agree with previous data presented in 325 
abstract form only from another large centre in the UK who found the median 326 
duration of treatment for their patients to be 11 months [15].  327 
 328 
As others have reported, our patients had several diabetes related comorbidities, 329 
including chronic kidney disease and retinopathy [21,22], suggesting that the 330 
development of CN and other microvascular disease may share a common 331 
pathway.  332 
 333 
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4 patients underwent below knee amputation (BKA) within the duration of the 334 
study. Of these, 1 patient had a neuropathic ulcer and the others had hindfoot 335 
Charcot’s with significant deformity at presentation. Of these, 2 declined to be put 336 
into a cast and deteriorated to a stage where their foot and ankle became 337 
unstable. All of the patients declined any reconstruction and their feet became 338 
unsalvageable.  The final patient deteriorated despite being in a TCC for 34 339 
weeks and developed significant ulceration and infection requiring amputation. 340 
Our study has shown an 8% amputation rate for patients with acute CN. Sohn et 341 
al suggested that the presence of an ulcer increased the likelihood of amputation 342 
12 fold [7]. Our amputation rate was higher than found by several recent studies, 343 
with the UK wide CDUK group reporting a 3.1% major amputation rate, and the 344 
2% reported by Sohn et al, but much lower than the rate reported by Gazis et al 345 
of 23.4% [12,7,23]. However, there remain concerns about the validity of their 346 
data because of the previously mentioned concerns – that the CDUK study had a 347 
degree of selection bias [12], and the data from Sohn et al also included data 348 
from several centres, and they too noted they were unable to obtain data on 349 
amputation rates from some centres, so their figures are likely to be an 350 
underestimate [7].  351 
 352 
The mortality reported in the present study is in line with previous work. 353 
Armstrong et al reported no deaths among 55 patients during a 92.6 week mean 354 
follow-up [19], with Fabrin et al reporting a 1.7% mortality among 115 patients 355 
during a 4 year follow up [14]. In contrast, Jeffcoate et al. showed a mortality of 356 
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44.7% amongst 47 patients with a mean of 3.7 year follow-up and a major 357 
amputation rate of 1.7% [23]. A more recent study showed a lower mortality of 358 
18.6% amongst 70 patients with CN after a median follow-up of 2.1 years, 359 
However, this was not statistically significantly different from the mortality rate 360 
amongst 66 matched control patients (p = 0.094) [24].  361 
 362 
There are few robust data describing the influence of anatomical location and 363 
rates of healing. However, our data are in contrast to previous work from a 364 
smaller cohort, that suggested that the duration of immobilisation may be 365 
influenced in part by the anatomical location of the CN [17].  366 
 367 
The strength of the current paper is that it is data from a single site with complete 368 
follow up on all of the patients. All of the patients were managed in the same way 369 
by the well-established diabetic foot MDT. Our team are able to offer our 370 
preferred initial treatment modality for Charcot, the TCC, in the diabetic foot clinic 371 
at the time of initial diagnosis, without delay.  372 
 373 
It has recently been suggested that the findings on MRI should be adopted as the 374 
criterion standard for establishing disease activity and diagnosing remission [25]. 375 
This is because MRI has the greatest potential to monitor the effect of treatment 376 
since it shows bone marrow oedema. However, the use of serial MRI as a tool to 377 
monitor for signs of disease remission was not used in our centre because it was 378 
not routinely recommended and remains a tool to be kept in reserve as 379 
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suggested in a recent systematic review [10]. There is emerging data to suggest 380 
that this should change, and MRI should be used more frequently [26]. 381 
 382 
Limitations include that our population is exclusively White Caucasian, and thus 383 
the generalizability may be limited when considering other populations. 384 
Furthermore, only 60% had a confirmed radiological diagnosis of a Charcot foot – 385 
with all of the others being radiologically normal, but with all of the other clinical 386 
features of a Charcot foot. The recommendations are to treat on clinical ground 387 
and not wait for radiological confirmation [10]. In addition, we feel that we have 388 
an excellent primary care network that refers to the specialist foot clinic early, 389 
thus preventing the development of bony deformity.  390 
 391 
We were unable to determine compliance with minimal weight bearing and the 392 
use of removable offloading devices when they were issued. Previous work has 393 
shown that compliance levels are low when devices are removable [27]. Future 394 
work may be able to use newer technologies to assess this.   395 
 396 
We are a tertiary referral centre, and over 15% of our work comes from other 397 
centres that are unable to apply a TCC. Patients are referred to us if there are no 398 
early signs of clinical resolution, usually in removable device. This is likely to lead 399 
to a longer time to resolution. Furthermore, there may have been a delay in the 400 
time between healing and the time for the patients to be provided with hospital 401 
footwear. During this time it was usual for patients to remain in the removable 402 
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device, thus artificially lengthening their time to resolution. However, this decision 403 
to classify resolution until footwear was available was deliberate, and in line with 404 
previous work [12], because for many patients this is the time that they are able 405 
to return to their former levels of activity, and thus more accurately reflects the 406 
personal impact of the disease on the patient.  407 
 408 
In summary, this work has shown that initial treatment with a TCC improves 409 
times to resolution for patients with acute CN. As a result of this work that all 410 
patients referred to us with a suspected CN are advised on the telephone when 411 
the appointment is being made, not to drive to their clinic appointment so that if a 412 
cast needs to be applied, there is no delay.  413 
 414 
However, a significant proportion of patients required re-immobilisation despite 415 
using recognised markers of resolution. This study highlights the need to develop 416 
more precise measures to help manage acute CN, and assess the impact of 417 
initial treatment modality on time to resolution. 418 
  419 
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Table 1 532 
 533 
Time to 
Improvement By 
Site Location 
N N 
Missing 
Mean SD Min Max Median IQ Range 
Active Charcot - 
forefoot 
5 0 47.2 22.6 14 68 50 (37,67) 
Active Charcot – 
midfoot 
27 2 56.2 30.3 16 159 53 (40,68) 
Active Charcot – 
Ankle/hindfoot 
8 4 51.8 23.1 12 79 53 (36.5,72) 
Mixed 2 0 53.0 39.6 25 81 53 (25,81) 
 534 
  535 
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Appendix 1. Summary of univariate results 
 
Results for continuous variables 
 
 
 
 
 
 
Variable Initial 
Device 
N Mean SD N 
Missing 
Minimum Maximum Median 95% CI IQ 
Range(25th,75th) 
P 
Time to Improvement Removable 17 53.5 23.1 0 14 98 53.0 (42.5,64.4) (37.0,68.0) 0.7681 
  TCC 25 54.6 31.1 6 12 159 48.0 (42.4,66.8) (38.0,67.0)  
DM Duration Removable 15 21.5 17.0 2 0 49 19.0 (12.9,30.1) (6.0,35.0) 0.4777 
 TCC 27 16.4 10.0 4 1 40 18.0 (12.7,20.2) (8.0,23.0)  
Age Removable 17 65.1 11.3 0 39 79 67.0 (59.8,70.5) (57.0,73.0) 0.2028 
  TCC 31 60.5 12.0 0 43 82 61.0 (56.3,64.8) (49.0,70.0)  
HbA1c Removable 17 63.2 17.6 0 37 101 61.0 (54.8,71.5) (53.0,67.0) 0.4444 
  TCC 31 67.8 21.0 0 42 115 61.0 (60.4,75.2) (52.0,85.0)  
Initial Device Duration Removable 17 11.8 13.0 0 1 41 7.0 (5.6,17.9) (1.0,14.0) 0.0014 
  TCC 31 27.8 19.2 0 2 82 26.0 (21.0,34.5) (15.0,35.0)  
Second Device Duration Removable 17 15.9 15.8 0 0 55 8.0 (8.4,23.5) (2.0,27.0) 0.7295 
  TCC 31 14.3 15.2 0 0 74 13.0 (8.9,19.6) (3.0,18.0)  
Time in TCC Removable 16 23.5 20.1 1 0 57 21.5 (13.7,33.3) (3.0,32.5) 0.2402 
 TCC 29 33 26.0 2 2 106 26.0 (23.6,42.5) (15.0,47.0)  
Time in Removable Device Removable 17 30.4 17.4 0 8 79 28.0 (22.1,38.7) (18.0,39.0) 0.0058 
  TCC 29 18.3 16.0 2 0 74 16.0 (12.5,24.2) (7.0,20.0)  
Number of Device changes Removable 17 4.1 2.6 0 1 9 3.0 (2.8,5.3) (3.0,5.0) 0.0579 
  TCC 31 2.9 2.2 0 1 12 2.0 (2.1,3.7) (2.0,4.0)  
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Summary of univariate results 
 
 
 
 
Variable Value N Number 
Missing 
Total TCC 
(N) 
TCC 
(%) 
Removable 
Device (N) 
Removable 
Device (%) 
P-value  
(Chi-square) 
DM Type Type 1 48 0 11 4 23.5 7 22.6 0.9404 
  Type 2   37 13 76.5 24 77.4  
Charcot Site Active Charcot – Forefoot  48 0 5 3 17.6 2 6.5 0.3814 
 Active Charcot – Midfoot   29 11 64.7 18 58.1  
 Active Charcot – Ankle/hindfoot   12 3 17.6 9 29.0  
 Mixed   0 0 0.0 2 6.5  
Re-plastered No 47 1 32 22 73.3 10 58.8 0.3052 
  Yes   15 8 26.7 7 41.2  
          
Precipitating Trauma No 47 1 33 21 70.0 12 70.6 0.9662 
 Yes   14 9 30.0 5 29.4  
Recent Foot Surgery No 47 1 41 26 83.9 15 93.8 0.3362 
 Yes   6 5 16.1 1 6.3  
Retinopathy No 48 0 9 4 12.9 5 29.4 0.1611 
 Yes   39 27 87.1 12 70.6  
Maculopathy No 48 0 33 20 64.5 13 76.5 0.3928 
 Yes   15 11 35.5 4 23.5  
Gender Male 48 0 32 21 67.7 11 64.7 0.8310 
 Female   16 10 32.3 6 35.3  
CKD Stage 0 and 1 48 0 11 7 22.6 4 23.5 0.6312 
 Stage 2   21 15 48.4 6 35.3  
  Stage 3 and 4     16 9 29.0 7 41.2   
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Figure 2
Patients identified by hospital 
database search – keyword 
‘Charcot’  
(n=330) 
Initial exclusions (n=251): 
Inappropriate referral letter 
(n=126), other diagnosis (n=50), 
unable to locate letter (n=14), 
chronic CN (n=61) 
Acute CN suspected (n=79) 
Suspected then excluded after 
history and examination 
(n=14) 
Acute CN diagnosed 
(n=50) 
Excluded (n=15): 
Ischaemic leg (n=3), patient 
not T1DM/T2DM (n=2), CN 
managed elsewhere (n=2), lost 
to follow up (n=3), declined 
management (n=2), notes 
unavailable (n=3) 
Included in data analysis (n=48) 
(n=50) 
Died (n=2) 
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